Easy-To-Trade Cannabis Stocks: Insights Into How Trading Activity Affects These Investments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2024
0mins
Should l Buy CRON?
Source: Benzinga
- Trading Volume and Liquidity: Trading volume reflects shares bought and sold, impacting liquidity in the stock market.
- High-Liquidity Cannabis Stocks: Examples like SNDL, Tilray Brands, Cronos Group, and Aurora Cannabis show strong liquidity.
- Pros of High-Liquidity Stocks: Reduced transaction costs, flexibility, and market confidence are advantages.
- Cons of High-Liquidity Stocks: Despite benefits, high trading volumes can lead to price volatility.
- Low-Liquidity Cannabis Stocks: Stocks like Medical Marijuana, Trees, Curaleaf Holdings, and Green Thumb Industries have lower liquidity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Cronos Launches Lord Jones® Brand in Israel, Expanding Global Reach
- Brand Expansion: Cronos Group has launched its premium cannabis brand Lord Jones® in Israel, marking a strategic expansion into one of the world's most advanced medical cannabis markets, aimed at meeting local demand and enhancing its global brand presence.
- Quality Commitment: The Lord Jones® cannabis flower is produced through carefully selected genetics and small-batch indoor cultivation, ensuring each batch undergoes rigorous testing and hand packaging to maintain aroma and quality, thereby enhancing trust among patients and pharmacists.
- Market Strategy: The launch introduces five premium indoor-grown flower strains and plans for future limited-edition products, demonstrating Cronos' long-term commitment to the Israeli market and its keen insight into the demand for high-end products.
- International Vision: CEO Mike Gorenstein emphasized Israel's key role in the company's borderless product strategy, with this expansion reflecting Cronos' determination and execution in promoting high-quality cannabis brands globally.
See More
Altria Reports $6.1B Q3 Revenue Amid 8.2% Decline in Cigarette Volumes
- Revenue Overview: Altria generated approximately $6.1 billion in revenue in Q3 2025, with its tobacco business contributing about $5.4 billion, highlighting the company's heavy reliance on this segment, while the ongoing decline in tobacco volumes poses a significant threat to future growth.
- Volume Decline: The company's cigarette volumes fell by 8.2% year-over-year in Q3 2025, with a 10.6% drop over the first nine months, indicating severe challenges in its core business that force it to raise prices to offset the impact of declining sales.
- Strategic Missteps: Altria's decision to spin off its international operations to Philip Morris International resulted in losing its most lucrative market while simultaneously creating a new competitor, reflecting significant errors in strategic decision-making.
- Investment Risks: Altria's investments in the vaping and marijuana sectors have both resulted in losses, particularly with Juul and Cronos Group, leading to substantial charges for shareholders, which exacerbates the company's difficulties in finding long-term growth avenues.
See More
Altria's Cigarette Sales Drop 10.6%, Offers 7.4% Dividend Yield
- Core Business Decline: Altria's cigarette sales fell by 8.2% in Q3 2025 compared to Q3 2024, with a 10.6% drop over the first nine months, indicating a long-term decline that threatens revenue stability.
- Market Share Challenges: While Altria holds a 40% overall market share and nearly 60% in the premium segment in the U.S., 88% of its cigarette sales come from the single brand Marlboro, exposing the company to significant brand concentration risk.
- Strategic Missteps: Altria's decision to spin off Philip Morris International has weakened its competitive position in international markets, and its investments in vaping and marijuana have resulted in billion-dollar write-offs, compounding financial pressures.
- Investor Caution: Despite a high dividend yield of 7.4% attracting some investors, the ongoing decline in core business and strategic missteps may lead many to avoid the stock, reflecting market concerns about its future growth potential.
See More
Altria Faces Declining Tobacco Sales with 7.4% Dividend Yield
- Declining Sales: Altria's cigarette sales fell by 8.2% in Q3 2025 compared to Q3 2024, with a 10.6% drop over the first nine months, indicating a long-term decline in its core business that could impact future cash flow and dividend sustainability.
- Market Share Concentration: While Altria holds a 40% overall market share and nearly 60% in the premium segment in the U.S., approximately 88% of its cigarette sales come from the single Marlboro brand, making it vulnerable to market shifts.
- Strategic Missteps: Altria's decision to spin off Philip Morris International has proven detrimental, as international cigarette sales have outperformed U.S. sales, leading to increased competition in the non-cigarette nicotine market.
- High Dividend Appeal: Despite its core business decline, Altria maintains a high dividend yield of 7.4%, attracting income-focused investors, but this also highlights the underlying risks and uncertainties in its business model.
See More
Noteworthy CRON Put and Call Options Set for February 2026
Put Contract Overview: The $2.50 put contract for CRON has a bid of 5 cents, allowing investors to potentially buy shares at a lower cost basis of $2.45, with a 79% chance of expiring worthless, offering a 2.00% return on cash commitment.
Call Contract Overview: The $3.50 call contract has a bid of 10 cents, enabling investors to sell shares at a 22.45% return if the stock is called away, with a 68% chance of expiring worthless, providing a potential 3.40% extra return.
Volatility Insights: The implied volatility for the put contract is 60% and for the call contract is 67%, while the actual trailing twelve-month volatility is calculated at 46%.
YieldBoost Concept: Both put and call contracts offer a "YieldBoost," with the put providing an annualized return of 11.59% and the call offering 19.71% if they expire worthless.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Cronos Launches Lord Jones® Brand in Israel, Expanding Global Reach
- Brand Expansion: Cronos Group has launched its premium cannabis brand Lord Jones® in Israel, marking a strategic expansion into one of the world's most advanced medical cannabis markets, aimed at meeting local demand and enhancing its global brand presence.
- Quality Commitment: The Lord Jones® cannabis flower is produced through carefully selected genetics and small-batch indoor cultivation, ensuring each batch undergoes rigorous testing and hand packaging to maintain aroma and quality, thereby enhancing trust among patients and pharmacists.
- Market Strategy: The launch introduces five premium indoor-grown flower strains and plans for future limited-edition products, demonstrating Cronos' long-term commitment to the Israeli market and its keen insight into the demand for high-end products.
- International Vision: CEO Mike Gorenstein emphasized Israel's key role in the company's borderless product strategy, with this expansion reflecting Cronos' determination and execution in promoting high-quality cannabis brands globally.
See More
Altria Reports $6.1B Q3 Revenue Amid 8.2% Decline in Cigarette Volumes
- Revenue Overview: Altria generated approximately $6.1 billion in revenue in Q3 2025, with its tobacco business contributing about $5.4 billion, highlighting the company's heavy reliance on this segment, while the ongoing decline in tobacco volumes poses a significant threat to future growth.
- Volume Decline: The company's cigarette volumes fell by 8.2% year-over-year in Q3 2025, with a 10.6% drop over the first nine months, indicating severe challenges in its core business that force it to raise prices to offset the impact of declining sales.
- Strategic Missteps: Altria's decision to spin off its international operations to Philip Morris International resulted in losing its most lucrative market while simultaneously creating a new competitor, reflecting significant errors in strategic decision-making.
- Investment Risks: Altria's investments in the vaping and marijuana sectors have both resulted in losses, particularly with Juul and Cronos Group, leading to substantial charges for shareholders, which exacerbates the company's difficulties in finding long-term growth avenues.
See More
Altria's Cigarette Sales Drop 10.6%, Offers 7.4% Dividend Yield
- Core Business Decline: Altria's cigarette sales fell by 8.2% in Q3 2025 compared to Q3 2024, with a 10.6% drop over the first nine months, indicating a long-term decline that threatens revenue stability.
- Market Share Challenges: While Altria holds a 40% overall market share and nearly 60% in the premium segment in the U.S., 88% of its cigarette sales come from the single brand Marlboro, exposing the company to significant brand concentration risk.
- Strategic Missteps: Altria's decision to spin off Philip Morris International has weakened its competitive position in international markets, and its investments in vaping and marijuana have resulted in billion-dollar write-offs, compounding financial pressures.
- Investor Caution: Despite a high dividend yield of 7.4% attracting some investors, the ongoing decline in core business and strategic missteps may lead many to avoid the stock, reflecting market concerns about its future growth potential.
See More
Altria Faces Declining Tobacco Sales with 7.4% Dividend Yield
- Declining Sales: Altria's cigarette sales fell by 8.2% in Q3 2025 compared to Q3 2024, with a 10.6% drop over the first nine months, indicating a long-term decline in its core business that could impact future cash flow and dividend sustainability.
- Market Share Concentration: While Altria holds a 40% overall market share and nearly 60% in the premium segment in the U.S., approximately 88% of its cigarette sales come from the single Marlboro brand, making it vulnerable to market shifts.
- Strategic Missteps: Altria's decision to spin off Philip Morris International has proven detrimental, as international cigarette sales have outperformed U.S. sales, leading to increased competition in the non-cigarette nicotine market.
- High Dividend Appeal: Despite its core business decline, Altria maintains a high dividend yield of 7.4%, attracting income-focused investors, but this also highlights the underlying risks and uncertainties in its business model.
See More
Noteworthy CRON Put and Call Options Set for February 2026
Put Contract Overview: The $2.50 put contract for CRON has a bid of 5 cents, allowing investors to potentially buy shares at a lower cost basis of $2.45, with a 79% chance of expiring worthless, offering a 2.00% return on cash commitment.
Call Contract Overview: The $3.50 call contract has a bid of 10 cents, enabling investors to sell shares at a 22.45% return if the stock is called away, with a 68% chance of expiring worthless, providing a potential 3.40% extra return.
Volatility Insights: The implied volatility for the put contract is 60% and for the call contract is 67%, while the actual trailing twelve-month volatility is calculated at 46%.
YieldBoost Concept: Both put and call contracts offer a "YieldBoost," with the put providing an annualized return of 11.59% and the call offering 19.71% if they expire worthless.
See More
